Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 16/20 | 0.55 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.47 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16101539 | 0.86 | BUB1 (0.51) | BUB1GUCY1A1GUCY1B1 | |
| SCHEMBL16102644 | 0.85 | BUB1 (0.52) | BUB1GUCY1A1GUCY1B1 | |
| SCHEMBL16100644 | 0.85 | BUB1 (0.76) | BUB1 | |
| SCHEMBL16103107 | 0.85 | BUB1 (0.59) | BUB1 | |
| SCHEMBL27557124 | 0.83 | ADORA3 (0.62) | GUCY1A1GUCY1B1 | |
| SCHEMBL16693496 | 0.82 | BUB1 (0.53) | BUB1GUCY1A1GUCY1B1CHRM1 | |
| SCHEMBL17511176 | 0.82 | BUB1 (0.49) | BUB1GUCY1A1GUCY1B1 | |
| SCHEMBL16101861 | 0.82 | BUB1 (0.48) | BUB1GUCY1A1GUCY1B1 | |
| SCHEMBL14843837 | 0.79 | BUB1 (0.67) | BUB1 | |
| SCHEMBL23162014 | 0.79 | GUCY1A1 (0.51) | BUB1GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283396-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283396-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283396-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20160052912-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2976334-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147144-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283396-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | BUB1 1/4885GUCY1A1 3470/4885GUCY1B1 2728/4885 |
| US-20160052912-A1 | DIAMINOHETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | BUB1 1/4885GUCY1A1 3470/4885GUCY1B1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.